Your browser doesn't support javascript.
loading
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
Du, Juan; Wei, Runhong; Jiang, Songfu; Jiang, Hua; Li, Lu; Qiang, Wanting; He, Haiyan; Shi, Lin; Ma, Qiuling; Yu, Kang; Zhang, Xiaoyuan; Ding, Hanyi; Sun, Xuedong; Xiang, Fang; Zhu, Lin; Cheng, Zhi; Fu, Weijun.
Afiliación
  • Du J; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Wei R; Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Jiang S; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Jiang H; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Li L; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Qiang W; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • He H; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Shi L; Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Ma Q; Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Yu K; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Zhang X; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Ding H; Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Sun X; HRAIN Biotechnology Co., Ltd., Shanghai, China.
  • Xiang F; HRAIN Biotechnology Co., Ltd., Shanghai, China.
  • Zhu L; HRAIN Biotechnology Co., Ltd., Shanghai, China.
  • Cheng Z; Department of Hematology, Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
  • Fu W; Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China.
Am J Hematol ; 97(7): 933-941, 2022 07.
Article en En | MEDLINE | ID: mdl-35488407
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Folicular / Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Folicular / Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: China